Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • Oct. 26, 2010, 7:52 AM
    Savient's (SVNT +4.4%) 44% drop yesterday may have been just what suitors were waiting for. With shares now trading near $12, potential bidders (like ABT, PFE, AMGN) might come back to the table and fair value may turn out to be closer to $20/share than the $47/share target some analysts had previously suggested.
    | Comment!
  • Oct. 25, 2010, 4:22 PM
    Amgen (AMGN): Q3 EPS of $1.36 beats by $0.09. Revenue of $3.8B (+0.1%) in-line. Shares -0.1% AH. (PR)
    | 1 Comment
  • Oct. 25, 2010, 12:10 AM
    Notable earnings after Monday's close: AMGN, ATHR, COG, DDR, EW, MAS, PCL, SLG, SNV, TXN, VECO, VRTX
    | Comment!
  • Oct. 20, 2010, 4:53 PM
    Stocks are "incredibly cheap" compared to bonds, Legg Mason's Bill Miller says - in fact, "It's the best time since the early 1980s" to buy stocks. His favorite picks now include: Merck (MRK), Amgen (AMGN), Hewlett-Packard (HPQ), Intel (INTC), Goldman Sachs (GS), Wells Fargo (WFC).
    | 11 Comments
  • Sep. 1, 2010, 11:48 AM
    Cash-rich and on the prowl, Amgen (AMGN) has said it may look for non-U.S. acquisitions to expand its international footprint; some analysts think the company is just playing games, making comments like these to disguise its interest in U.S.-based firms, possibly including HGSI and DNDN.
    | Comment!
  • Jul. 29, 2010, 4:27 PM
    Amgen (AMGN): Q2 EPS of $1.38 beats by $0.08. Revenue of $3.8B (+2.5%) vs. $3.7B. Shares +0.2% AH. (PR)
    | Comment!
  • Jul. 29, 2010, 12:10 AM
    Notable earnings after Thursday's close: AMGN, APKT, CSTR, DTE, EMN, EXPE, FSLR, GNW, IM, KLAC, MET, MFE, MWW, MXIM, PTV, RGC, ROVI, RSG, SUN, VALE, WFR
    | Comment!
  • Jun. 21, 2010, 9:54 AM
    Affymax (AFFY -63.4%) shares plunge on data that shows safety risks for its anemia drug Hematide. Non-dialysis patients taking the drug had a higher rate of cardiovascular events, including heart attacks, strokes and death, than those taking Amgen's (AMGN +4.1%) Epogen.
    | 1 Comment
  • Jun. 2, 2010, 3:57 PM
    Amgen (AMGN +10.8%) shares soar today after the FDA clears marketing of its Prolia drug as a treatment for postmenopausal osteoporosis.
    | Comment!
  • Jun. 2, 2010, 9:00 AM
    Premarket gainers: GNA +59%. DIVX +30%. AVII +9%. ABK +7%. HERO +7%. ARNA +6%. CTIC +5%. AMGN +5%. TSEM +5%. IRE +4%.
    Losers: CSIQ -19%. PVG -7%. AIB -5%.
    | Comment!
  • Jun. 2, 2010, 7:28 AM
    Amgen (AMGN +4.4%) gets key FDA clearance for Prolia, its injectable bone strengthening drug. It's a potential blockbuster market, and analysts believe Amgen could make billions of dollars in revenue from Prolia's launch.
    | 1 Comment
  • May 28, 2010, 9:23 AM
    Amgen's (AMGN) new drug Prolia for treatment of osteoporosis wins approval for sale in Europe. GlaxoSmithKline (GSK) will market the drug, throwing its weight behind a product that industry analysts expect to make billions of dollars in annual sales. AMGN +1%, GSK +1.7% premarket. (PR)
    | Comment!
  • Apr. 21, 2010, 4:19 PM
    Amgen (AMGN): Q1 EPS of $1.30 beats by $0.06. Revenue of $3.59B (+8.6%) vs. $3.65B. Shares -1.9% AH. (PR)
    | Comment!
  • Apr. 21, 2010, 12:10 AM
    Notable earnings after Wednesday's close: ACF, ADS, AFFX, AMGN, CPX, CTXS, CVA, CYH, EBAY, ETFC, FFIV, FNF, HCBK, ISIL, LEG, LRCX, MEE, NE, NFLX, NVLS, PLCM, PTV, QCOM, SBUX, SLM, SNDK, TER, TEX, URI, VRTX
    | Comment!
  • Feb. 16, 2010, 9:55 AM
    New Medicare rules may help little-known Affymax (AFFY +0.2%) grab market share from Amgen's (AMGN -0.2%) $2.6B anemia drug Epogen with a treatment set to be approved next year.
    | Comment!
  • Jan. 25, 2010, 4:10 PM
    Amgen (AMGN): Q4 EPS of $1.05 misses by $0.08. Revenue of $3.8B (+2%) vs. $3.85B. Expects fiscal 2010 capex of about $600M. Shares -0.4% AH. (PR)
    | Comment!
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States